Patent details
301238
Product Name:
Deucravacitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
Ok
Cancel
You have not selected any documents
Ok
Basic Information
Publication number:
301238
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP2922846
Status:
SPC granted but not yet in force
Application number:
301238
Procedural language:
Dutch
First Applicant Residence Country:
United States of America (US)
Marketing Authorization
Marketing Authorization Number:
EU/1/23/1718
Marketing Authorization Type:
EEA
Marketing Authorization Date:
27/03/2023
Marketing Authorization Country:
European Union (EU)
Dates
Filing date:
24/07/2023
First Marketing Authorization date:
27/03/2023
Grant date:
04/10/2023
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
24/07/2023
SPC/SPC Extension Expiration Date:
26/03/2038
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:
Applicant/holder
From:
24/07/2023
Name:
Bristol-Myers Squibb Company
Address:
Route 206 and Province Line Road, PRINCETON, NJ 08543, United States of America (US)
Agent
Name:
dr. R.C. van Duijvenbode c.s.
From:
24/07/2023
Address:
NLO
Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:
Publication
Bulletin
1
Bulletin Heading:
SPC
Journal edition number:
41/23
Publication date:
11/10/2023
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
2
Bulletin Heading:
SPC
Journal edition number:
30/23
Publication date:
26/07/2023
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Annual Fee
Annual Fee(s) Due Date:
30/11/2033
Annual Fee Number:
21
Annual Fee Amount:
1600 Euro
Last Annual Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date
Document type
Document Description
Number of pages
File Type
04/10/2023
Outgoing Correspondence
Decision grant
1
PDF
/5/4/1/0/0/0800900145/docs/301238_9_569391l504a.pdf
04/10/2023
Certificate
Certificate
1
PDF
/5/4/1/0/0/0800900145/docs/301238_10_spcmedcertificate20231004094732003.pdf
24/07/2023
Application Form
First filed application form
2
PDF
/5/4/1/0/0/0800900145/docs/301238_0_applicationform20230724095447545.pdf
24/07/2023
SPC Documents
Annex SPC
4
PDF
/5/4/1/0/0/0800900145/docs/301238_1_supplprotectioncertificate20230724095535528.pdf
24/07/2023
SPC Documents
Marketing Authorization SPC
3
PDF
/5/4/1/0/0/0800900145/docs/301238_2_supplprotectioncertificate20230724103706595.pdf
24/07/2023
SPC Documents
Annex SPC
11
PDF
/5/4/1/0/0/0800900145/docs/301238_3_supplprotectioncertificate20230724103736115.pdf
24/07/2023
SPC Documents
Summary of the characteristics of the product
15
PDF
/5/4/1/0/0/0800900145/docs/301238_4_supplprotectioncertificate20230724095844426.pdf
24/07/2023
SPC Documents
Annex SPC
2
PDF
/5/4/1/0/0/0800900145/docs/301238_5_supplprotectioncertificate20230724095844464.pdf
24/07/2023
SPC Documents
Annex SPC
12
PDF
/5/4/1/0/0/0800900145/docs/301238_6_supplprotectioncertificate20230724095844497.pdf
24/07/2023
SPC Documents
Annex SPC
2
PDF
/5/4/1/0/0/0800900145/docs/301238_7_supplprotectioncertificate20230724103821458.pdf
24/07/2023
Outgoing Correspondence
Confirmation receipt request
2
PDF
/5/4/1/0/0/0800900145/docs/301238_8_557119l174.pdf